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Abstract
Radiometals are the mainstay of both diagnostic and therapeutic nuclear medicine because the choice of
radionuclide is primarily dictated by nuclear decay characteristics rather than chemistry. 99mTC is the most
frequently used diagnostic radionuclide and requires coordination in a diversity of chemical disguises to
permit imaging ofa variety of tissues and disease states. Therapeutic nuclear medicine is less advanced but
can provide significant benefits provided the radionuclide is accurately targetted.
Introduction
Radiopharmaceuticals are radioactive drugs which can have either diagnostic or therapeutic applications. In
diagnostic nuclear medicine, the radionuclide is used as a tracer to provide functional information about the
tissue under investigation. The very short-lived positron-emitting radionuc|ides such as IC, 3N, 150 and
are used for diagnosis in hospitals with access to highly specialised and expensive positron emission
tomography (PET) facilities. However, most hospital nuclear medicine departments are not equipped for such
work and need to use radionuclides suitable for single photon emission tomography (SPET). The nuclear
properties required for such radionuclides are:
1. A half-life long enough both to make it readily available in the hospital and to allow it to be distributed
in vivo according to the physiological function being investigated, but not so long as to give the patient
more radiation dose than is justified by the requirements of the study. These needs frequently dictate a
half-life of2-3 days.
2. A decay which gives rise to penetrating y-emissions to allow the distribution of the radionuclide to be
measured, but is not accompanied by damaging, non-penetrating particulate radiations such as c- or
particles.
In contrast, therapeutic radionuclides should have particulate radiations with an in vivo range sufficient to
destroy the target tissue but not so long as to cause collateral damage and have little or no accompanying ,-
emissions which could cause unnecessary radiation exposure to both the patient and hospital staff. Again, the
half-lifeneeds to be sufficiently long to allow availability to the hospital and in vivo distribution but is
otherwise dictated by whether the radiation dose is to be delivered at a high dose rate over a short time or at
a lower dose rate over an extended period. The use of radionuclides in therapy is less advanced than in
diagnosis because destructive doses require much more accurate targeting than tracer doses.
The nuclear requirements for either diagnosis or therapy are seldom met by the radionuclides of the
biologically ubiquitous elements such as C, H, N, O etc. but oblige the use of biologically unimportant or
irrelevant elements, almost all of which are metallic. Although some radiometals will target a particular
tissue when administered as a simple metal salt, it is frequently the case that the radiopharmaceutical chemist
is required to coordinate the metal in a chemical Trojan Horse to cause it to be delivered to its biological
target. The role of coordination chemistry in nuclear: medicine has been reviewed by Jurisson et af. This
paper will illustrate the use of radiometals in nuclear medicine by discussing the use of the 99mTC
coordination compounds 99mTc-HM-PAO for imaging cerebral blood flow and 99mTc-HL91 under
development for imaging hypoxic tissue and the application of89Sr as the chloride salt for the treatment of
metastatic bone pain.
The Role of 99mTC in Diagnostic Nuclear Medicine
Tc is a second row transition metal which did not occur on Earth before its artefactualproduction, mainly as
a product of 235U fission. 99mTC has nuclear decay characteristics which make it the most frequently used
diagnostic radionuclide. It decays with a 6.02 hour half-life by isomeric transition to 99Tc. The decay is
accompanied by the emission of a 140 keV y-ray (89%)which is near-ideal for imaging with a modem y-
camera. Although 99Tc is itself radio9a9mCtive (decaying by [3-emission with a half-lifeof 2.1x10 years), the
quantities produced by the decay of Tc radiopharmaceuticals are not usually considered hazardous the
ratio of 99Tc radioactivity to originating 99mTc radioactivity is the ratio of the half-lives,-1 to 3 108. The
short half-life of 99mTc is long enough to be suitable for most nuclear medicine procedures but usually
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precludes convenient distribution from manufacturer to hospital radiopharmacy. However, 99mTC is produced
by the decay of 66-hour half-life99Mo. Distribution is achieved by the supply of commercially produced
99"Mo/99mTC generators. These contain an alumina chromatography column on which 99M0 has been adsorbed
from acidified molybdate solution. The 99mTc is extracted as 9mTcO4" by elution with 0.9% NaC1 to produce
a sterile solution which is isotonic with blood and ready for injection. The chromatography column is
"99 surrounded by a lead or depleted uranium shield. As the 99mTC is continuously produced by the Mo decay,
the generator can be eluted one or more times a day. The decay and regrowth characteristics are illustrated in
Figure for a variety of elution times. The calculation of these curves is described in most radiochemistry or
nuclear chemistry textbooks (e.g. reference 2).
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Figure 1" 99Mo/99mTC generator elution and regrowth.
99m with near o tmal It is seen that the generator system allows preparation of WcO4 once or twice a day p"
efficiency of 99mTC use. Although 99mTcO4" has nuclear medicine uses in its own right, such as thyroid
imaging, the majority of applications for 99mTC require it to be in other chemical forms. Tc exhibits a range of
oxidation states from-1 to +7. The Tc in 99mTco4" is in oxidation state +7 and requires reduction and
coordination with a suitable ligand system to provide an appropriately targeted radiopharmaceutical. Most
99m 99n Tc radopharmaceutcals are produced from TcO4 with the aid of commercially produced kits, either in
the hospital or at a centralised radiopharmacysupplying many hospitals in a region. The simplest and most
convenient technetium kits consist of a sterile vial containing a freeze-driedmixture of a reducing agent
(usually a salt of Sn(II)), a complexing agent and perhaps some excioients such as a filler or a buffer. On
addition of generator eluate and any required 0.9% NaC1 diluent, the 99tnTcO4" reacts with the kit ingredients
to produce a finished radiopharmaceutical in just a few minutes.
The Use of99mT-HM-PAO for Imaging Brain Blood Flow
Imaging of brain blood flow is used for the diagnosis and management of patients with a wide variety of
neurological and psychiatric conditions such as stroke, epilepsy, trauma, depression and dementias of various
99m origins. In the 1980 s, the discovery of Tc-based agents for imaging brain blood flow was an important
goal for radiopharmaceutical research. The need for the molecule to cross the intact blood-brain barrier (BBB)
< dctated that t should be electrically neutral, of low molecular mass 500 daltons) and lpophlc. Several
99m 99m TM Tc complexes were identified as potential brain blood flow agents but only Tc-HM-PAO (Ceretec
99m 99m Amersham International) and Tc-ECD have progressed to routine clinical use. The development of Tc-
HM-PAO stemmed from the discovery that the 99mTC complex ofPnAO (Figure 2)6 possesses the properties
required to cross the BBB and shows transient flow-related brain uptake in humans. It is formed by reacting
99mTcO4" with Sn(II) and PnAO to cause reduction of the Tc from oxidation state +7 to +5 and complexation
by the PnAO ligand to give a lipophilic neutral molecule. The Tc-PnAO did not persist in the brain for long
enough to permit imagine using conventional SPET equipment. Synthesis of a range ofPnAO derivatives
led to the discovery of 99nTc-HM-PAO3. This molecule is unstable in aqueous solution, reacting to produce
99m a poorly characterised hydrophilic Tc complex. Its in vivo behaviour appears to be similar except that the
intracellularrate ofconversion to a hydrophilic complex is sufficiently fast to cause -50% of the 99mTC that
enters brain to be trapped7. The greatly enhanced rate of conversion in vivo appears to be due to reaction with
intracellular glutathione. The trapping arises because the conversion product is too hydrophilic to cross the
BBB and so is unable to diffuse out of the brain. The resultant distribution of 99mTC within the brain gives a
snapshot of blood flow at the time of injection. Figure 3 illustrates this with planar (as opposed to
tomographically reconstructed SPET) scans of normal and brain-dead subjects the radioactivity is only
deposited in viable tissue. Figure 4 shows SPET images of a trauma patient 2 weeks after injury and
following recovery. The scans give detailed information about the progression of brain function.
154James F. Burke Metal-Based Drugs
PnAO Tc-PnAO HM-PAO Tc-HM-PAO
Figure 2" Amine oxime ligands and complexes. The HM-PAO used is the d,l-racemate.
Figure 3: Planar ’Tc-HM-PAO brain scans of normal and brain-dead subjects. The dense radioactivity
distribution in the normal subject is consistent with the regional distribution of brain blood flow. In the
brain-dead subject, radioactivity is concentrated in the catheter used for administering the injection but is
absent from the brain. 99mTc-HM-PAO is normally administered by intravenous injection in the arm. (Images
reproduced courtesy of Dr D. C. Costa8, University College London Medical School, London, UK).
The Development of 99mTc--HL91 for Imaging Hypoxic Tissue
The imaging of hypoxic (under-oxygenated)tissue is of potential importance because it may allow the
identification and management oftumours resistant to radiotherapy or of at risk myocardium (hea muscle) in
heart patients. A possible targeting mechanism is the intracellular reduction of nitroimidazoles (Figure 5).
The in vivo reduction of nitroimidazoles is mediated by cytosolic or mitochondrial enzymes but, in
normoxic (normally oxygenated)cells, the first step is reversed due to reaction with oxygen (the "futile
cycle"). In hypoxic cells, this reversal does not take place and products which may be unable to diffuse out of
the cell occur.
The first 99mTC agent to employ this trapping mechanism was BMS-181321 (Figure 6). Inspection of
Figure 2 shows this is formed from a nitroimidazole derivative of PnAO. While BMS-181321 exhibits
uptake and retention in hypoxic tissue, its very high lipophilicity results in poor clearance from background
tissue, especially the liver. A Tc complex of HLgl (also known as Bn(AO)z)has been described by
Jurisson et al. That work identified the complex as containing a trans-Tc02 core. However, subsequent
studies suggest a variety of complexes can be formed, depending on the preparation route 13. Work at
Amersham International identified the 99mTc complex formed in aqueous solution from the HLgl
nitroimidazole derivative, HLglM as a useful lead compoundTM. However, negative control experiments
showed, the. analogous14 99mTc complex of the underivatised HLgl ligand gave more selective retention" m"
hypoxc tssue The complex has subsequently been shown to be reducible under conditions similar to
those required to reduce nitroimidazoles r3. 99Tc-HLgl is still undergoing development as a hypoxia
imaging agent. Figure 7 shows scans of a head tumour comparing a PET metabolism image
deoxyglucose, SFDG)with a 99mTc-HLgl SPET image- this is one of the first patient studies with 99mTC-
HL91.
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Figures 4" 99mTc-HM-PAO brain SPET scans of an assault victim showing very low 99mTC deposition in the
frontal lobes 2 weeks after the injury and a near-normal distribution following recovery. (Images reproduced
courtesy of Dr D J Wyper, Southern General Hospital, Glasgow, UK).
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Figure 5" Intracellular reduction ofnitroimidazoles.
The Use of 89Sr-SrCi for the Treatment of Metastatic Bone Pain
Prostate cancer is the second most common male cancer in many Westem countries. Most cases are detected
too late for curative treatment. Metastases (secondary cancers)usually appear in bone. Bone pain is a
1"5 n common problem which is often difficult to control effectively .Management ofbone pa’n ofte progresses
through the following stages: hormone treatment; chemotherapy and/or local radiotherapy and/or analgesics;
hemibody radiotherapy; narcotics. Once these measures have failed as the disease progresses, the quality of
life of such patients is frequently poor. At this stage, the use of a therapeutic radiopharmaceutical that
concentrates at the sites of lesions to provide in situ radiotherapy can be an attractive option.
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Figure 6: Amine oxime derivatives developed for imaging hypoxia.
Figure 7" Tomographically reconstructed images of a transaxial section of the head of a patient with a head
tumour- a lymphoma arising either from the skull or the soft tissue overlying the skull. The tumour is in
the left frontal region but the patient’s left and right are transposed in the images. Left image: 18F-
deoxyglucose PET scan showing normal glucose metabolism in the brain and a region of high glucose
99m metabolism corresponding to the tumour. Right image" 99mTc-HL91 SPET scan showing intense Tc
deposition in the tumour but very little radioactivity elsewhere. (Images reproduced courtesy of Dr G Cook,
Guy’s Hospital, London, UK).
Sr
2+ can behave as an analogue ofCa
2+ both metals are in group IIA ofthe periodic table; the ionic radii (2+)
are 11.3 nm and 9.9 nm respectively). Sr decays by emission of a 1.49 MeV (maximum energy) 13-particle
with a half-life of 50.5 days. The -emission has a range in bone of 3.5 mm. There are no accompanying ’- emissions. Tracer studies with the y-emitting nuclide’SSSr show Sr administered intravenously as a solution
16 85 of SrCI2 is taken up in bone, concentrating at sites of high bone turnover The Sr washed out of normal
85 bone but was retained at metastatic sites. Sr not incorporated in bone was excreted in the urine. Whole
body retention of 85Sr at 3 months following injection varied from 88% in a patient with complete skeletal
involvement to 11% in light disease. Consequently, 89SrC12 (MetastronTM, Amersham International) may be
administered by intravenous injection and concentrate in fast-growing regions of bone, such as metastases,
destroying the metastatic tissue and causing reliefof pain. Studies to establish the optimum dosage were
conducted in 112 patients7. There was a positive dose-pain relief response relationship which rose to a
plateau at 1.5 MBq/kg. The major side-effects were depression of platelets and leukocytes. At a dose of 150
MBq (-2.15 MBq/kg), the three-month post treatment levels had dropped-30% for platelets and -20% for
leukocytes. This was adopted as the standard dose to allow for patient variation, whilst ensuring side-effects
were kept below unacceptable levels. A double-blind study was conducted to compare patient response to
150 MBq S9Sr with response to placebo1. Patients used diaries to record their symptoms and intake of
analgesic. Assessment also took into account the level of pain, appetite, mood and slee9 pattern. By the time
final assessments were available from 26 patients, the study was terminated because Sr exhibited a clear
superiority and it became unethical to continue administering placebo. The results are shown in Figure 8.
One third of patients showed a dramatic response to S9Sr, whereas none showed such a response to placebo.
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Figure 8: Assessment of response of patients to 89Sr (n=12) and placebo (n=14).
Conclusions
Radiometals are the mainstay of both diagnostic and therapeutic nuclear medicine because the choice of
radionuclide is primarily dictated by nuclear decay characteristics rather than chemistry. Although some
metals are usefully targeted as simple salts, most uses require the application of carefully researched
coordination chemistry to ensure delivery of the radionuclide to the target tissue.
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